Raw Powder Factory Supply 99% Purity Lanreotide Acetate CAS 127984-74-1

Lanreotide Acetate

Overview
Lanreotide acetate is the acetate salt of lanreotide. Lanreotide is a somatostatin analog with similar properties to octreotide; it is used to treat acromegaly and symptomatic neuroendocrine tumors. Acromegaly is a rare disease caused by excessive secretion of growth hormone (GH) by somatotropin-producing pituitary adenomas. Patients usually suffer from changes in body structure and endocrine metabolic disorders due to excessive GH and insulin-like growth factor (IGF-1), which seriously affects their quality of life and life span. Long-acting somatostatin analogs (SSA) represented by lanreotide acetate can effectively inhibit GH secretion, reduce tumor volume, and significantly improve patients' quality of life. They are the first choice for drug treatment. On December 18, 2019, lanreotide acetate sustained-release injection (prefilled) was officially approved by the National Medical Products Administration (NMPA) for the treatment of acromegaly when the levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in the blood are still abnormal after surgery and/or radiotherapy, or when surgery and/or radiotherapy cannot be performed, opening a new era of treatment. It brings a new option for the drug treatment of acromegaly with its innovative formulation process, rich evidence of efficacy, and extraordinary user experience. In fact, Lanreotide Acetate Sustained-Release Injection (Prefilled) has been registered and marketed in about 70 countries around the world and is one of the long-acting SSAs recommended by multiple domestic and foreign guidelines and consensus.